Accent Microcell Ltd
Incorporated in 2012, Accent Microcell Ltd manufactures Pharmaceutical Excipients[1]
- Market Cap ₹ 1,108 Cr.
- Current Price ₹ 462
- High / Low ₹ 481 / 211
- Stock P/E 25.3
- Book Value ₹ 115
- Dividend Yield 0.21 %
- ROCE 24.9 %
- ROE 18.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 54.3% CAGR over last 5 years
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 114 | 131 | 133 | 166 | 197 | 246 | 265 | 349 | |
| 108 | 122 | 122 | 153 | 178 | 206 | 223 | 292 | |
| Operating Profit | 6 | 9 | 11 | 13 | 19 | 39 | 42 | 57 |
| OPM % | 5% | 7% | 8% | 8% | 10% | 16% | 16% | 16% |
| 6 | 4 | 2 | 2 | 2 | 3 | 6 | 7 | |
| Interest | 3 | 3 | 3 | 3 | 3 | 1 | 0 | 1 |
| Depreciation | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 |
| Profit before tax | 5 | 6 | 6 | 8 | 15 | 37 | 44 | 58 |
| Tax % | 24% | 31% | 20% | 22% | 17% | 17% | 24% | 25% |
| 4 | 4 | 5 | 6 | 12 | 30 | 33 | 44 | |
| EPS in Rs | 7.39 | 8.53 | 9.80 | 4.01 | 8.26 | 12.57 | 13.78 | 18.28 |
| Dividend Payout % | 0% | 0% | 9% | 18% | 8% | 7% | 6% | 5% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 21% |
| TTM: | 32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 54% |
| 3 Years: | 53% |
| TTM: | 33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 110% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 21% |
| Last Year: | 19% |
Balance Sheet
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 13 | 13 | 21 | 21 | 24 |
| Reserves | 17 | 21 | 22 | 19 | 37 | 143 | 174 | 252 |
| 32 | 30 | 31 | 24 | 23 | 13 | 2 | 1 | |
| 20 | 22 | 23 | 38 | 37 | 28 | 32 | 45 | |
| Total Liabilities | 73 | 77 | 81 | 95 | 111 | 205 | 228 | 322 |
| 30 | 29 | 30 | 30 | 31 | 29 | 48 | 53 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 2 | 13 | 102 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 43 | 48 | 50 | 64 | 79 | 174 | 168 | 167 | |
| Total Assets | 73 | 77 | 81 | 95 | 111 | 205 | 228 | 322 |
Cash Flows
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 6 | 5 | 5 | 15 | 8 | 11 | 25 | 19 | |
| -4 | -2 | -6 | -4 | -4 | -82 | -9 | -49 | |
| -1 | -2 | -2 | -10 | -4 | 72 | -14 | 36 | |
| Net Cash Flow | 1 | 1 | -3 | 1 | -1 | 1 | 2 | 6 |
| Free Cash Flow | 2 | 3 | -0 | 11 | 3 | -2 | -12 | -68 |
| CFO/OP | 120% | 72% | 57% | 127% | 53% | 44% | 85% | 56% |
Ratios
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 70 | 60 | 35 | 38 | 56 | 80 | 90 | 95 |
| Inventory Days | 67 | 78 | 128 | 128 | 128 | 83 | 76 | 55 |
| Days Payable | 89 | 80 | 74 | 97 | 106 | 48 | 42 | 33 |
| Cash Conversion Cycle | 48 | 58 | 88 | 68 | 79 | 114 | 124 | 117 |
| Working Capital Days | 19 | 30 | 37 | 16 | 41 | 79 | 101 | 95 |
| ROCE % | 18% | 17% | 19% | 27% | 31% | 24% | 25% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Total Installed Capacity MTPA |
|
|||
| Capacity Utilization - Dahej Plant % |
||||
| Capacity Utilization - Pirana Plant % |
||||
| Export Share of Revenue % |
||||
| In-house Manufactured Goods Proportion % |
||||
| Traded Goods Proportion % |
||||
| Domestic Share of Revenue % |
||||
| Number of Countries Presence Count |
||||
| Number of MCC Grades Count |
||||
| Top 10 Customer Revenue Concentration % |
||||
| In-house Manufactured Volume MT |
||||
| Pharma Segment Revenue Share % |
||||
| Semi-processed/Traded Volume MT |
||||
| Total Volume Sold MT |
||||
| Unit I (Pirana) Capacity MTPA |
||||
| Unit II (Dahej) Capacity MTPA |
||||
| Unit III (Kheda) - Phase 1 Capacity MTPA |
||||
Extracted by Screener AI
Documents
Announcements
-
Updates
13 May 2026 - Unit-III at Nayka, Kheda delayed; environment and power approvals pending before trial run and commercial production.
-
Analysts/Institutional Investor Meet/Con. Call Updates
13 May 2026 - Accent Microcell to hold investor call on 16 May 2026 for H2 and FY26 audited results.
-
Copy of Newspaper Publication
13 May 2026 - Audited half-year/year ended March 31, 2026 results published in Financial Express on May 13, 2026.
-
Statement of deviation(s) or variation(s) under Reg. 32
12 May 2026 - Accent Microcell Limited has informed about statement of deviation(s) or variation(s) under Reg. 32
-
Dividend
12 May 2026 - Board at its meeting held on May 12, 2026, recommended Final Dividend of Rs. 1.00 per equity share.
Annual reports
Concalls
-
Aug 2025TranscriptPPTREC
-
May 2025Transcript PPT REC
-
Jan 2025TranscriptPPTREC
-
Mar 2024TranscriptPPTREC
Business Overview:[1]
AMC is an EXCiPACT, US-DMF, GMP, ISO 9001:2008, HACCP certified manufacturer and exporter of 22 different grades of Microcrystalline Cellulose (MCC). It caters to 10+ sectors and services 200+ customers in India and worldwide.